Provided by Tiger Fintech (Singapore) Pte. Ltd.

Esperion Therapeutics

0.9492
+0.01952.10%
Post-market: 0.95000.0008+0.08%19:48 EDT
Volume:4.93M
Turnover:4.79M
Market Cap:187.80M
PE:-3.43
High:1.06
Open:0.9813
Low:0.9300
Close:0.9297
Loading ...

Esperion Therapeutics -Pursuant to Agreements, Co to Issue $100 Mln of 5.75% Convertible Notes Due 2030

THOMSON REUTERS
·
13 Dec 2024

Press Release: Esperion Announces $210 Million Convertible Debt Financing

Dow Jones
·
13 Dec 2024

Esperion Therapeutics Price Target Maintained With a $16.00/Share by HC Wainwright & Co.

Dow Jones
·
13 Dec 2024

Esperion Therapeutics Signs Licensing Deal for Nexletol, Nexlizet in Israel

MT Newswires Live
·
12 Dec 2024

Esperion entered into licensing agreement with Neopharm Israel

TIPRANKS
·
12 Dec 2024

BRIEF-Esperion Partners With Neopharm To Commercialize Nexletol® (Bempedoic Acid) And Nexlizet® (Bempedoic Acid And Ezetimibe) In Israel

Reuters
·
12 Dec 2024

Esperion Partners With Neopharm to Commercialize Nexletol® (Bempedoic Acid) and Nexlizet® (Bempedoic Acid and Ezetimibe) in Israel

THOMSON REUTERS
·
12 Dec 2024

Esperion Therapeutics Inc: Under Terms of Agreement, Esperion Will Receive an Upfront and Near-Term Milestone Payments

THOMSON REUTERS
·
12 Dec 2024

Esperion selloff continues following competitor data from NewAmsterdam

TIPRANKS
·
12 Dec 2024

ESPR Files New Drug Submissions for Nexletol & Nexlizet in Canada

Zacks
·
03 Dec 2024

Esperion Shares Rise After New Canadian Drug Submissions

Dow Jones
·
03 Dec 2024

Esperion Therapeutics Price Target Maintained With a $16.00/Share by HC Wainwright & Co.

Dow Jones
·
02 Dec 2024

Esperion Therapeutics Files Applications for Non-Statin Medications in Canada

MT Newswires Live
·
02 Dec 2024

BRIEF-Esperion Announces New Drug Submissions in Canada for NEXLETOL and NEXLIZET Treatments to Reduce LDL-C and Cardiovascular Risk

Reuters
·
02 Dec 2024

Esperion: New Drug Submissions in Canada for Nexletol and Nexlizet Treatments to Reduce Ldl-C and Cardiovascular Risk

THOMSON REUTERS
·
02 Dec 2024

Esperion Therapeutics Price Target Maintained With a $16.00/Share by HC Wainwright & Co.

Dow Jones
·
27 Nov 2024

Esperion Therapeutics' Bempedoic Acid Submitted for Approval in Japan by Otsuka Pharmaceutical

MT Newswires Live
·
26 Nov 2024

BRIEF-Otsuka Submits New Drug Application In Japan For Bempedoic Acid In The Treatment Of Hypercholesterolemia

Reuters
·
26 Nov 2024

Otsuka Submits New Drug Application in Japan for Bempedoic Acid in the Treatment of Hypercholesterolemia

THOMSON REUTERS
·
26 Nov 2024

Esperion Therapeutics Inc - No Serious Adverse Events Observed in Bempedoic Acid Trial

THOMSON REUTERS
·
26 Nov 2024